Navigation Links
Neogen Reactivates Share Repurchase Program

LANSING, Mich., March 9 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) announced today that on March 6 it initiated its current common stock repurchase program. In December, Neogen's Board of Directors authorized the repurchase of up to 500,000 shares.

Shares have been, and additional shares are expected to be, acquired on the open market or in negotiated transactions, depending on market conditions and other factors. Accordingly, there is no guarantee of the exact number of shares to be repurchased. Shares repurchased under the program will be retired. The company had 14,600,000 shares outstanding on Nov. 30, 2008.

"The price of Neogen shares is at the lowest level in nearly two years," said James Herbert, Neogen's CEO. "We believe the price is an extraordinary value given the company's fundamentals and performance that have withstood the worst overall economy in decades."

Neogen's second quarter was the 63rd consecutive profitable quarter from operations for the company, and the 67th quarter of the past 72 quarters to show increased revenues as compared with the previous year--a span of 18 years. Neogen will announce results for the third quarter of its 2009 fiscal year, which ended Feb. 28, on Thursday, March 19.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.

SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Webcast Alert: Neogen Corporation To Announce 2nd Quarter Results
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. NeoGenomics to Present at the Noble Financial Equity Conference
5. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
6. NeoGenomics Announces Results for the 3rd Quarter 2007
7. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
8. Stimulating Thymus Reactivates T-Cell Production
9. Consumer Group Wants Public to Share Profits From Federally Funded Stem Cell and Medical Research
10. Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger
11. Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: